These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19250131)

  • 1. Editorial: Moving the QALY forward or just stuck in traffic?
    Johnson FR
    Value Health; 2009 Mar; 12 Suppl 1():S38-9. PubMed ID: 19250131
    [No Abstract]   [Full Text] [Related]  

  • 2. Moving the QALY forward: rationale for change.
    Smith MD; Drummond M; Brixner D
    Value Health; 2009 Mar; 12 Suppl 1():S1-4. PubMed ID: 19250124
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message.
    Garrison LP
    Value Health; 2009 Mar; 12 Suppl 1():S36-7. PubMed ID: 19250130
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of quality-adjusted life-years in cost-effectiveness studies.
    Sculpher M
    Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
    [No Abstract]   [Full Text] [Related]  

  • 5. Retaining, and enhancing, the QALY.
    Lipscomb J; Drummond M; Fryback D; Gold M; Revicki D
    Value Health; 2009 Mar; 12 Suppl 1():S18-26. PubMed ID: 19250127
    [No Abstract]   [Full Text] [Related]  

  • 6. What do utilities measure?
    Tsevat J
    Med Care; 2000 Sep; 38(9 Suppl):II160-4. PubMed ID: 10982102
    [No Abstract]   [Full Text] [Related]  

  • 7. Toward a consensus on the QALY.
    Drummond M; Brixner D; Gold M; Kind P; McGuire A; Nord E;
    Value Health; 2009 Mar; 12 Suppl 1():S31-5. PubMed ID: 19250129
    [No Abstract]   [Full Text] [Related]  

  • 8. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
    Richardson G; Manca A
    Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision processes in the management of dental disease. Part 1: QALYs, QATYs and dental health state utilities.
    Fyffe HE; Nuttall NM
    Dent Update; 1995 Mar; 22(2):67-71. PubMed ID: 10495696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of health economic decisions in actual practice: the role of behavioral economics. Summary of the presentation given by Professor Daniel Kahneman at the ISPOR 10th Annual International Meeting First Plenary Session, May 16, 2005, Washington, DC, USA.
    Value Health; 2006; 9(2):65-7. PubMed ID: 16626409
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of single-level anterior cervical discectomy and fusion five years after surgery.
    Carreon LY; Anderson PA; Traynelis VC; Mummaneni PV; Glassman SD
    Spine (Phila Pa 1976); 2013 Mar; 38(6):471-5. PubMed ID: 22986842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses.
    Angevine PD; Berven S
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S9-15. PubMed ID: 25299265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.
    Villacorta R; Hay JW; Messali A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):545-58. PubMed ID: 24820676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuing health for clinical and economic decisions: directions relevant for rheumatologists.
    Harrison MJ; Bansback NJ; Marra CA; Drummond M; Tugwell PS; Boonen A
    J Rheumatol; 2011 Aug; 38(8):1770-5. PubMed ID: 21807800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legislating against use of cost-effectiveness information.
    Neumann PJ; Weinstein MC
    N Engl J Med; 2010 Oct; 363(16):1495-7. PubMed ID: 20942664
    [No Abstract]   [Full Text] [Related]  

  • 20. Preference-based outcome measures in cost-utility analyses. A 20-year overview.
    Greenberg D; Pliskin JS
    Int J Technol Assess Health Care; 2002; 18(3):461-6. PubMed ID: 12391940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.